Strontium ranelate in the prevention of osteoporotic fractures

[en] Osteoporosis results from a decrease in bone strength yielding increased susceptibility to fractures. Hip and spine fractures are a major cause of morbidity and mortality in the elderly population. With an increasingly ageing world population, early prevention of bone loss is essential for adequate control of this condition. Strontium ranelate (PROTELOS (R)), an oral drug for postmenopausal osteoporosis, has been reported to decrease bone resorption and to stimulate bone formation. The efficacy in reducing vertebral fractures, non-vertebral including hip fractures, and the safety of strontium ranelate has been initially demonstrated over 3 years in the SOTI (Spinal Osteoporosis Therapeutic Intervention) and TROPOS (TReatment Of Peripheral OSteoporosis) studies and confirmed recently over up to 5 years. A preplanned analysis of a sub-group of patients aged 80 years and over showed that, currently, strontium ranelate is the only antiosteoporotic agent to reduce vertebral and non-vertebral fractures in this age group.

Disciplines :

Pharmacy, pharmacology & toxicology
General & internal medicine

Author, co-author :

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Malaise, Olivier ; Université de Liège - ULiège > Cert.ECG

NEUPREZ, Audrey ; Université de Liège - ULiège > Département des Sciences de la Santé Publique > Epudémiologie et santé publique

Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Language :

English

Title :

Strontium ranelate in the prevention of osteoporotic fractures

Publication date :

February 2007

Journal title :

International Journal of Clinical Practice

ISSN :

1368-5031

eISSN :

1742-1241

Publisher :

Blackwell Publishing, Oxford, United Kingdom

Volume :

Issue :

Pages :

324-328

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 26 August 2009

Statistics

Number of views

94 (8 by ULiège)

Number of downloads

5 (5 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

The European Prospective Osteoporosis Study (EPOS) Group. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002; 17: 716-24.
Kanis JA, Johnell O, Oden A et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000; 27: 585-90.
Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001; 69: 121-9.
Melton LJ III, Johnell O, Lau E et al. Osteoporosis and the global competition for health care resources. J Bone Miner Res 2004; 19: 1055-8.
Takahashi N, Sasaki T, Tsuoderos Y, Suda TS. 12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 2003; 18: 1082-7.
Baron R, Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 2002; 450: 11-17.
Brennan TC, Rybchyn MS, Conigrave AD, Mason RS. Strontium ranelate effect on proliferation and OPG expression in osteoblasts. Calcif Tissue Int 2006; 78 (Suppl. 1): S129 (p356).
Canalis E, Hott M, Deloffre P et al. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996; 18: 517-23.
Boivin G, Meunier PJ. The mineralization of bone tissue: a forgotten dimension in osteoporosis research. Osteoporos Int 2003; 14 (Suppl. 3): S19-24.
Ammann P, Shen V, Robin B et al. Strontium ranelate improves bone resistance by increasing bone mass. J Bone Miner Res 2004; 19: 2012-20.
Buehler J, Chappuis P, Saffar JL et al. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001; 29: 176-9.
Reginster JY. Strontium ranelate in osteoporosis. Curr Pharm Des 2002; 8: 1907-16.
Marie PJ, Hott M, Modrowski D et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993; 18: 607-15.
Hott M, Deloffre P, Tsouderos Y, Marie PJ. S12911-2 reduces bone loss induced by short-term immobilization in rats. Bone 2003; 33: 115-23.
Geoffroy V, Marty C, Lalande A, de Vemejoul M-C. Strontium ranelate reduces new vertebral fractures in a severe osteoporotic mouse model with spontaneous fractures by improving bone microarchitecture. Osteoporos Int 2006; 17 (Suppl. 2): 0S93 (P329SU).
Meunier PJ, Slosman DO, Delmas PD et al. Strontium ranelate: dose-dependent effects in established postmenopausal osteoporosis - a 2-year randomised placebo controlled trial. J Clin End Metab 2002; 87: 2060-6.
Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-68.
Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of non-vertebral fractures in postmenopausal women with osteoporosis: TROPOS study. J Clin End Metab 2005; 90: 2816-22.
Boivin G, Farlay D, Simi C, Meunier PJ. Bone strontium distribution and degree of mineralization of bone in postmenopausal osteoporotic women treated with strontium ranelate for 2 and 3 years. Osteoporos Int 2006; 17 (Suppl. 2): S86 (P310SA).
Jiang Y, Zhao JJ, Genant HK. Effects of strontium ranelate on 3D cortical and trabecular microstructure in postmenopausal osteoporosis in multicenter, double-blind and placebo controlled studies. Osteoporos Int 2006; 18: 2.
Reginster JY, Meunier PJ, Roux C et al. Strontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti-fracture efficacy over 5 years in post-menopausal women. Osteoporos Int 2006; 17 (Suppl. 2): S14.
Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-3.
Roux C, Reginster JY, Fechtenbaum J et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 2006; 21: 536-42.
Seeman E, Vellas B, Benhamou CL et al. Strontium ranelate reduces the risk of vertebral and non-vertebral fractures in women aged eighty years and over. J Bone Miner Res 2006; 21: 1113-20.
Seeman E, Vellas B, Benhamou CL et al. Sustained 5-year vertebral and non-vertebral fracture risk reduction with strontium ranelate in elderly women with osteoporosis. Osteoporos Int 2006; 18: 1-13 (OC39).
Feldstein A, Elmer PJ, Orwoll E et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 2003; 163: 2165-72.
Kanis JA, Dawson A, Oden A et al. Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 2001; 12: 356-61.
Boonen S, McClung MR, Eastell R et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Amer Geriatr Soc 2004; 52: 1832-9.
Boonen SJ, Marin F, Mellstrom D et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006; 54: 782-9.